



Corporate Office Address :  
Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
info@infiniumpharmachem.com, infinium\_11@yahoo.com  
+91-2692-238849, 238850, 297446  
www.infiniumpharmachem.com

R.O. & Factory Address :  
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
Gujarat, India Tel/fax : +91-2697-234987, 296000  
CIN NO : U24231GJ2003PLC043218

May17, 2023

To,  
The Manager, Listing Department,  
National Stock Exchange of India Limited  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
NSE Symbol: INFINIUM

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. With reference to the captioned subject and in furtherance to our intimation letter dated May 03, 2023, we hereby inform the stock exchange that the Board of Directors of the company at its meeting held today i.e. **Wednesday May 17, 2023** inter-alia decided as under:

1. Considered and approved the standalone audited financial results of the Company for the year ended on March 31, 2023.
2. Considered and approved the consolidated audited financial results of the Company for the year ended on March 31, 2023.
3. Considered and approved the appointment of Mr. Piyush P Sutariya & Co. Chartered Accountant as internal auditor for the Financial Year 2023-24.
4. Considered and approved the appointment of M/s RTBR & Associates as Secretarial auditor for the Financial Year 2023-24.
5. Review of Business

Kindly note that the meeting of the Board of Directors of the Company commenced at **11:30 a.m.** and concluded at **2.50 p.m.**

We request you to kindly take the same on record.

Thanking You,

Yours Sincerely,

**For Infinium Pharmachem Limited**

SANJAYKUMAR  
VITHALBHAI PATEL  
Digitally signed by  
SANJAYKUMAR VITHALBHAI  
PATEL  
Date: 2023.05.17 14:53:27 +05'30'

**Sanjaykumar Viththalbhai Patel**

**Managing Director**

**DIN: 00370715**



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

| STATEMENT OF STANDALONE ASSETS AND LIABILITIES |                |                |
|------------------------------------------------|----------------|----------------|
|                                                |                | (Rs. In Lacs)  |
| PARTICULAR                                     | As At          | As At          |
|                                                | 31.03.2023     | 31.03.2022     |
|                                                | Audited        | Audited        |
| <b>A. ASSETS</b>                               |                |                |
| <b>1. NON CURRENT ASSETS</b>                   |                |                |
| (a) Property, Plant and Equipment              | 1558.03        | 374.30         |
| (b) Intangible Assets                          | 0.00           | 0.00           |
| (c) Capital Work in Progress                   | 0.00           | 847.95         |
| (d) Intangible Assets under development        | 0.00           | 0.00           |
| (e) Non Current Investments                    | 34.11          | 26.46          |
| (f) Deffered Tax assets(Net)                   | 5.16           | 6.74           |
| (g) Long term Loans and Advances               | 31.10          | 11.42          |
| (h) Other Assets                               | 13.00          | 245.48         |
| <b>Total Non Current Assets</b>                | <b>1641.39</b> | <b>1512.34</b> |
| <b>2. CURRENT ASSETS</b>                       |                |                |
| (a) Inventories                                | 1791.34        | 1422.71        |
| (b) Financial Assets                           |                |                |
| (i) Current Investments                        | 0.00           | 0.00           |
| (ii) Trade Receivable                          | 1516.02        | 1294.87        |
| (iii) Cash and Cash Equivalents                | 331.51         | 154.45         |
| (iv) Other Balance With Banks                  | 0.06           | 0.03           |
| (v) Loans and Advances                         | 739.16         | 466.37         |
| (vi) Other Asstes                              | 22.33          | 54.88          |
| <b>Total Current Assets</b>                    | <b>4400.44</b> | <b>3393.33</b> |
| <b>TOTAL ASSETS</b>                            | <b>6041.83</b> | <b>4905.67</b> |
| <b>B. EQUITY AND LIABILITIES</b>               |                |                |
| <b>1. EQUITY</b>                               |                |                |
| (a) Equity Share Capital                       | 508.31         | 101.66         |
| (b) Other Equity                               | 1661.59        | 1153.32        |
| <b>Total Equity</b>                            | <b>2169.89</b> | <b>1254.98</b> |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

|                                            |                                                                                            |                |
|--------------------------------------------|--------------------------------------------------------------------------------------------|----------------|
| <b>2. LIABILITY</b>                        |                                                                                            |                |
| <b>NON-CURRENT LIABILITIES</b>             |                                                                                            |                |
| (a) Financial Liabilities                  | 0.00                                                                                       | 0.00           |
| (b) Deferred Tax Liabilities               | 0.00                                                                                       | 0.00           |
| (c) Other Non Current Liabilities          | 763.05                                                                                     | 1362.38        |
| Total Non Current Liabilities              | 763.05                                                                                     | 1362.38        |
| <b>CURRENT LIABILITIES</b>                 |                                                                                            |                |
| (a) Financial Liabilities                  |                                                                                            |                |
| (i) Trade Payables                         | 877.82                                                                                     | 1024.92        |
| (1) Total outstanding dues of MSME.        | 20.65                                                                                      | 1.99           |
| (2) Total outstanding dues Otherthan MSME. | 857.17                                                                                     | 1022.93        |
| (ii) Other Financial Liabilities           | 1846.45                                                                                    | 889.68         |
| (b) Other Current Liabilities              | 0.72                                                                                       | 14.95          |
| (c) Provisions                             | 74.81                                                                                      | 168.44         |
| (d) Income tax Liabilities                 | 309.09                                                                                     | 190.31         |
| Total Current Liabilities                  | 3108.89                                                                                    | 2288.31        |
| <b>TOTAL</b>                               | <b>6041.83</b>                                                                             | <b>4905.67</b> |
|                                            |                                                                                            |                |
|                                            | <b>For, INFINIUM PHARMACHEM LTD</b>                                                        |                |
|                                            | Digitally signed by<br>SANJAYKUMAR VITHTHALBHAI PATEL<br>Date: 2023.05.17 14:55:16 +05'30' |                |
|                                            | <b>Sanjay V Patel</b>                                                                      |                |
| <b>Place : Sojitra</b>                     | <b>Chairman</b>                                                                            |                |
| <b>Date : 17/05/2023</b>                   | <b>DIN No. : 00370715</b>                                                                  |                |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

| STATEMENT OF STANDALONE FINANCIAL RESULT FOR THE YEAR ENDED ON 31st MARCH, 2023 |                                        |                                        |
|---------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|
|                                                                                 |                                        | (Rs. In Lacs)                          |
| PARTICULARS                                                                     | For the Year ended<br>31st March, 2023 | For the Year ended<br>31st March, 2022 |
| <b>INCOME</b>                                                                   |                                        |                                        |
| Revenue from Operations                                                         | 10130.62                               | 7403.77                                |
| Other Income, net                                                               | 134.34                                 | 92.55                                  |
| <b>TOTAL INCOME</b>                                                             | <b>10264.96</b>                        | <b>7496.32</b>                         |
| <b>EXPENSES</b>                                                                 |                                        |                                        |
| Cost of Matetrial Consumed                                                      | 7152.53                                | 5421.69                                |
| Purchases of Traded Goods                                                       | 0.00                                   | 0.00                                   |
| Changes In Inventories of FG., WIP.                                             | -96.79                                 | -20.30                                 |
| Employee Benefits Expenses                                                      | 366.62                                 | 316.15                                 |
| Financial Cost                                                                  | 299.65                                 | 165.74                                 |
| Deprecaition and Amortization Expenses                                          | 128.91                                 | 58.19                                  |
| Other Expenses                                                                  | 1187.56                                | 814.32                                 |
| <b>TOTAL EXPENSES</b>                                                           | <b>9038.47</b>                         | <b>6755.78</b>                         |
| <b>Profit Before eceptional and extraordinary Items</b>                         | <b>1226.49</b>                         | <b>740.54</b>                          |
| Exceptional Items                                                               | 0.00                                   | 0.00                                   |
| <b>Profit Before Taxes</b>                                                      | <b>1226.49</b>                         | <b>740.54</b>                          |
| Tax Expenses                                                                    |                                        |                                        |
| (a) Current Tax                                                                 | 309.09                                 | 190.31                                 |
| (b) Deffered Tax (Liabilies)/Assets                                             | 1.58                                   | 1.03                                   |
| (c) Prior Year Tax (Liabilies)/Assets                                           | 0.90                                   | 0.92                                   |
| <b>Profit (Loss) for the period</b>                                             | <b>914.92</b>                          | <b>550.34</b>                          |
| Earing per equity share                                                         |                                        |                                        |
| (a) Basic                                                                       | 18.00                                  | 54.13                                  |
| (b) Dilluted                                                                    | 18.00                                  | 54.13                                  |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

|                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Notes For Standalone Financial Results :                                                                                                                                                                                                                                                                                                                                     |                                                                                                  |
| 1. The above audited Standalone Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2023 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 17th May, 2023                                                                                                       |                                                                                                  |
| 2. The above Standalone Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2023 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. |                                                                                                  |
| 3. Being the Company is listed on 17th April, 2023 and Half yearly result during the financial year 2021-22 are not applicable to the company that years and it is not prepared and audited hence half yearly data are not given.                                                                                                                                            |                                                                                                  |
| 4. The company had made an initial public issue (SME -IPO) of 18,75,000 equity shares of face value of Rs. 10/- fully paid up for cash at a price of Rs 135/- per equity share (including share premium of Rs. 125/- per equity share) aggregating to Rs. 2525.72 Lakhs. SME- IPO opened for public on 31st March, 2023 and listed on NSE -SME Platform on 17th April, 2023. |                                                                                                  |
| 5. The management is in process of identifying parties which are covered under MSME, the amount relating to MSME are disclosed to the extent identified.                                                                                                                                                                                                                     |                                                                                                  |
| 6. In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company                                                                                                                                                                                                                             |                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                              | <b>For, INFINIUM PHARMACHEM LTD</b>                                                              |
|                                                                                                                                                                                                                                                                                                                                                                              | SANJAYKUMAR                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                              | VITHTHALBHAI                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                              | PATEL                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                              | Digitally signed by<br>SANJAYKUMAR<br>VITHTHALBHAI PATEL<br>Date: 2023.05.17<br>14:55:37 +05'30' |
|                                                                                                                                                                                                                                                                                                                                                                              | <b>Sanjay V Patel</b>                                                                            |
| <b>Place : Sojitra</b>                                                                                                                                                                                                                                                                                                                                                       | <b>Chairman</b>                                                                                  |
| <b>Date : 17/05/2023</b>                                                                                                                                                                                                                                                                                                                                                     | <b>DIN No. : 00370715</b>                                                                        |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
info@infiniumpharmachem.com, infinium\_11@yahoo.com  
+91-2692-238849, 238850, 297446  
www.infiniumpharmachem.com

**R.O. & Factory Address :**  
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
Gujarat, India Tel/fax : +91-2697-234987, 234004  
CIN No U24231GJ2003PLC043218

| <b>STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31st MARCH, 2023</b> |                                        |                                        |
|------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|
|                                                                              |                                        | (Rs. In Lacs)                          |
| Particular                                                                   | For the Year ended<br>31st March, 2023 | For the Year ended<br>31st March, 2022 |
| <b>A. Cash Flow from Operating Activities</b>                                |                                        |                                        |
| <b>Net Profit / (Loss) before Tax</b>                                        | <b>1226.49</b>                         | <b>740.54</b>                          |
| <b>Adjustments for :</b>                                                     |                                        |                                        |
| Depreciation and Amortization                                                | 128.91                                 | 58.19                                  |
| Financial Cost                                                               | 299.65                                 | 165.74                                 |
| Interest Received                                                            | -1.34                                  | -2.44                                  |
| Other Non Operating income                                                   | 0.00                                   | 0.00                                   |
| <b>Operating Profit before working capital changes</b>                       | <b>1653.71</b>                         | <b>962.02</b>                          |
| <b>Adjustments for (increase)/Decrease in operating assets :</b>             |                                        |                                        |
| Trade Receivable                                                             | -221.15                                | -252.15                                |
| Inventories                                                                  | -368.63                                | -556.02                                |
| Loans and Advances                                                           | -272.79                                | -268.59                                |
| Other Current Assets                                                         | 32.55                                  | -54.78                                 |
| <b>Adjustments for increase/(Decrease) in operating liabilities :</b>        |                                        |                                        |
| Trade Payable                                                                | -147.10                                | -113.83                                |
| Other Non Current Laibilities                                                | -599.33                                | 783.07                                 |
| Other Financial Liabilities- Current                                         | 956.77                                 | 417.78                                 |
| Other Current Liabilities                                                    | -14.24                                 | 10.81                                  |
| Provisions                                                                   | 25.15                                  | 176.56                                 |
| <b>Increase / (Decrease) in Non Current Assets</b>                           |                                        |                                        |
| Cash Generated From Operations                                               | 1044.94                                | 1104.88                                |
| Direct Tax                                                                   | 309.99                                 | 191.23                                 |
| Indirect Tax                                                                 |                                        |                                        |
| <b>Net Cash From Operating Activities (A)</b>                                | <b>734.94</b>                          | <b>913.65</b>                          |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
info@infiniumpharmachem.com, infinium\_11@yahoo.com  
+91-2692-238849, 238850, 297446  
www.infiniumpharmachem.com

**R.O. & Factory Address :**  
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
Gujarat, India Tel/fax : +91-2697-234987, 234004  
CIN No U24231GJ2003PLC043218

|                                                                       |                                     |                                   |
|-----------------------------------------------------------------------|-------------------------------------|-----------------------------------|
| <b>B. Cash Flow from Investing Activities</b>                         |                                     |                                   |
| Purchase of Tangible Fixed Assets (Gross)                             | -464.68                             | -469.54                           |
| Purchase of Intangible Fixed Assets (Gross)                           | 0.00                                | 0.00                              |
| Increase / (Decrease) in Non Current Assets                           | 0.00                                | 0.00                              |
| Long term Loans and Advances                                          | -19.68                              | -4.57                             |
| Other Non Current Assets                                              | 232.48                              | -245.48                           |
| Other Non Current Investments                                         | -7.65                               | 0.00                              |
| Interest Received                                                     | 1.34                                | 2.44                              |
| Other Non Operating income                                            | 0.00                                | 0.00                              |
| <b>Net Cash used in Investing Activities (B)</b>                      | <b>-258.20</b>                      | <b>-717.14</b>                    |
|                                                                       |                                     |                                   |
| <b>C. Cash Flow from Financing Activities</b>                         |                                     |                                   |
| Proceeds from Issuing share                                           | 0.00                                | 0.00                              |
| Interest /Finacial Charges Paid                                       | -299.65                             | -165.74                           |
| <b>Net Cash used in Financing Activities (c)</b>                      | <b>-299.65</b>                      | <b>-165.74</b>                    |
|                                                                       |                                     |                                   |
| <b>Net Increase / (Decrease) in cash and cash equivalents (A+B+C)</b> | <b>177.09</b>                       | <b>30.77</b>                      |
| <b>Cash and cash equivalents at the beginning of the year</b>         | <b>154.48</b>                       | <b>123.71</b>                     |
| <b>Cash and cash equivalents at the end of the year</b>               | <b>331.58</b>                       | <b>154.48</b>                     |
|                                                                       |                                     |                                   |
|                                                                       | <b>For, INFINIUM PHARMACHEM LTD</b> |                                   |
|                                                                       | SANJAYKUMAR                         | Digitally signed by SANJAYKUMAR   |
|                                                                       | VITHTHALBHAI                        | VITHTHALBHAI PATEL                |
|                                                                       | PATEL                               | Date: 2023.05.17 14:55:52 +05'30' |
|                                                                       | <b>Sanjay V Patel</b>               |                                   |
| <b>Place : Sojitra</b>                                                | <b>Chairman</b>                     |                                   |
| <b>Date : 17/05/2023</b>                                              | <b>DIN No. : 00370715</b>           |                                   |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

| STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES |                       |                       |
|--------------------------------------------------|-----------------------|-----------------------|
|                                                  |                       | (Rs. In Lacs)         |
| PARTICULARS                                      | For the year ended on | For the year ended on |
|                                                  | 31st March,2023       | 31st March,2022       |
| <b>A. ASSETS</b>                                 |                       |                       |
| <b>I. NON CURRENT ASSETS</b>                     |                       |                       |
| (a) Property, Plant and Equipment                | 1880.64               | 419.96                |
| (b) Intangible Assets                            | 0.00                  | 0.00                  |
| (c) Capital Work in Progress                     | 0.00                  | 847.95                |
| (d) Intangible Assets under development          | 0.00                  | 0.00                  |
| (e) Non Current Investments                      | 0.00                  | 0.00                  |
| (f) Deffered Tax assets(Net)                     | 5.16                  | 6.74                  |
| (g) Long term Loans and Advances                 | 31.10                 | 11.42                 |
| (h) Other Assets                                 | 13.00                 | 245.48                |
| <b>Total Non Current Assets</b>                  | <b>1929.90</b>        | <b>1531.54</b>        |
| <b>2. CURRENT ASSETS</b>                         |                       |                       |
| (a) Inventories                                  | 1971.72               | 1636.12               |
| (b) Financial Assets                             |                       |                       |
| (i) Current Investments                          | 0.00                  | 0.00                  |
| (ii) Trade Receivable                            | 1543.23               | 1539.19               |
| (iii) Cash and Cash Equivalents                  | 597.95                | 545.13                |
| (iv) Other Balance With Banks                    | 0.06                  | 0.03                  |
| (v) Loans and Advances                           | 679.79                | 492.93                |
| (vi) Other Asstes                                | 338.56                | 155.01                |
| <b>Total Current Assets</b>                      | <b>5131.31</b>        | <b>4368.41</b>        |
| <b>TOTAL ASSETS</b>                              | <b>7061.22</b>        | <b>5899.95</b>        |
| <b>B. EQUITY AND LIABILITIES</b>                 |                       |                       |
| <b>1. EQUITY</b>                                 |                       |                       |
| (a) Equity Share Capital                         | 508.31                | 101.66                |
| (b) Other Equity                                 | 1747.83               | 1208.56               |
|                                                  | 2256.13               | 1310.22               |
| (c) Non Controlling Interest                     | 122.07                | 81.93                 |
| <b>Total Equity</b>                              | <b>2378.20</b>        | <b>1392.15</b>        |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

|                                      |                                     |                           |
|--------------------------------------|-------------------------------------|---------------------------|
| <b>2. LIABILITY</b>                  |                                     |                           |
| <b>NON-CURRENT LIABILITIES</b>       |                                     |                           |
| (a) Financial Liabilities            | 0.00                                | 0.00                      |
| (b) Deferred Tax Liabilities         | 0.00                                | 0.00                      |
| (c) Other Non Current Liabilities    | 1006.11                             | 1362.38                   |
| <b>Total Non Current Liabilities</b> | <b>1006.11</b>                      | <b>1362.38</b>            |
| <b>CURRENT LIABILITIES</b>           |                                     |                           |
| (a) Financial Liabilities            |                                     |                           |
| (i) Trade Payables                   | 682.77                              | 1181.68                   |
| (ii) Other Financial Liabilities     | 1917.88                             | 889.68                    |
| (b) Other Current Liabilities        | 682.56                              | 711.72                    |
| (c) Provisions                       | 84.61                               | 168.44                    |
| (d) Income tax Liabilities           | 309.09                              | 193.89                    |
| <b>Total Current Liabilities</b>     | <b>3676.91</b>                      | <b>3145.42</b>            |
| <b>TOTAL</b>                         | <b>7061.22</b>                      | <b>5899.95</b>            |
|                                      | <b>For, INFINIUM PHARMACHEM LTD</b> |                           |
|                                      | SANJAYKUMAR                         | Digitally signed by       |
|                                      | VITHTHALBHAI                        | <del>SANJAYKUMAR</del>    |
|                                      | PATEL                               | VITHTHALBHAI PATEL        |
|                                      |                                     | Date: 2023.05.17 14:56:24 |
|                                      |                                     | +05'30'                   |
|                                      | <b>Sanjay V Patel</b>               |                           |
| <b>Place : Sojitra</b>               | <b>Chairman</b>                     |                           |
| <b>Date : 17/05/2023</b>             | <b>DIN No. : 00370715</b>           |                           |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

| STATEMENT OF CONSOLIDATED FINANCIAL RESULT FOR THE YEAR ENDED ON 31st MARCH, 2023 |                       |                       |
|-----------------------------------------------------------------------------------|-----------------------|-----------------------|
|                                                                                   |                       | (Rs. In Lacs)         |
| PARTICULARS                                                                       | For the year ended On | For the year ended On |
|                                                                                   | 31st March, 2023      | 31st March, 2022      |
| <b>INCOME</b>                                                                     |                       |                       |
| Revenue from Operations                                                           | 11422.49              | 9911.93               |
| Other Income, net                                                                 | 135.16                | 93.32                 |
| <b>TOTAL INCOME</b>                                                               | <b>11557.64</b>       | <b>10005.25</b>       |
| <b>EXPENSES</b>                                                                   | 0.00                  | 0.00                  |
| -                                                                                 | 0.00                  | 0.00                  |
| Cost of Material Consumed                                                         | 7152.53               | 5421.69               |
| Purchases of Traded Goods                                                         | 864.44                | 2413.99               |
| Changes In Inventories of FG., WIP.                                               | 40.14                 | -162.00               |
| Employee Benefits Expenses                                                        | 537.11                | 354.04                |
| Financial Cost                                                                    | 310.48                | 170.25                |
| Depreciation and Amortization Expenses                                            | 133.88                | 63.12                 |
| Other Expenses                                                                    | 1223.76               | 880.93                |
| <b>TOTAL EXPENSES</b>                                                             | <b>10262.34</b>       | <b>9142.02</b>        |
| <b>Profit Before Exceptional &amp; Extraordinary Items</b>                        | <b>1295.30</b>        | <b>863.23</b>         |
| Exceptional Items                                                                 | 0.00                  | 0.00                  |
| <b>Profit Before Taxes</b>                                                        | <b>1295.30</b>        | <b>863.23</b>         |
| <b>Tax Expenses</b>                                                               | 0.00                  | 0.00                  |
| (a) Current Tax                                                                   | 311.09                | 193.89                |
| (b) Deffered Tax (Liabilities)/Assets                                             | 1.58                  | 1.03                  |
| (c) Prior Year Tax (Liabilities)/Assets                                           | 0.90                  | 1.80                  |
| Profit after tax for the year                                                     | <b>981.73</b>         | <b>668.57</b>         |
| Less : Non Controlling Interest                                                   | 32.74                 | 57.93                 |
| Profit (Loss) for the period                                                      | <b>948.99</b>         | <b>610.64</b>         |
| Earing per equity share                                                           |                       |                       |
| (a) Basic                                                                         | 18.67                 | 60.07                 |
| (b) Dilluted                                                                      | 18.67                 | 60.07                 |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
**info@infiniumpharmachem.com, infinium\_11@yahoo.com**  
**+91-2692-238849, 238850, 297446**  
**www.infiniumpharmachem.com**

**R.O. & Factory Address :**  
Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
Gujarat, India Tel/fax : +91-2697-234987, 234004  
**CIN No U24231GJ2003PLC043218**

|                                                                                                                                                                                                                                                                                                                                                                                  |                                     |                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------|
| Notes For Standalone Financial Results :                                                                                                                                                                                                                                                                                                                                         |                                     |                     |
| 1. The above audited Consolidated Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2023 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 17th May, 2023                                                                                                         |                                     |                     |
| 2. The above Consolidated Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2023 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognised accounting practices and policies, as applicable. |                                     |                     |
| 3. Following subsidiary company has been considered in the preparation of consolidated financial statements for the year ended on 31st March, 2023                                                                                                                                                                                                                               |                                     |                     |
| Name of the entity                                                                                                                                                                                                                                                                                                                                                               | Country Of Incorporation            | % Of Holding        |
| Shanghai Tajilin Industrial Co. Limited                                                                                                                                                                                                                                                                                                                                          | China                               | 51%                 |
| Infinium Green Energy Private Limited                                                                                                                                                                                                                                                                                                                                            | India                               | 51%                 |
| 3. Being the Company is listed on 17th April, 2023 and Half yearly result during the financial year 2021-22 are not applicable to the company that years and it is not prepared and audited hence half yearly data are not given.                                                                                                                                                |                                     |                     |
| 4. The company had made an initial public issue (SME -IPO) of 18,75,000 equity shares of face value of Rs. 10/- fully paid up for cash at a price of Rs 135/- per equity share (including share premium of Rs. 125/- per equity share) aggregating to Rs. 2525.72 Lakhs. SME- IPO opened for public on 31st March, 2023 and listed on NSE -SME Platform on 17th April, 2023.     |                                     |                     |
| 5. The management is in process of identifying parties which are covered under MSME, the amount relating to MSME are disclosed to the extent identified.                                                                                                                                                                                                                         |                                     |                     |
| 6. In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been reviewed by the Statutory Auditors of the Company                                                                                                                                                                                                                                 |                                     |                     |
|                                                                                                                                                                                                                                                                                                                                                                                  |                                     |                     |
|                                                                                                                                                                                                                                                                                                                                                                                  |                                     |                     |
|                                                                                                                                                                                                                                                                                                                                                                                  | <b>For, INFINIUM PHARMACHEM LTD</b> |                     |
|                                                                                                                                                                                                                                                                                                                                                                                  | SANJAY KUMAR                        | Digitally signed by |
|                                                                                                                                                                                                                                                                                                                                                                                  | VITHALBHAI                          | SANJAY KUMAR        |
|                                                                                                                                                                                                                                                                                                                                                                                  | PATEL                               | VITHALBHAI PATEL    |
|                                                                                                                                                                                                                                                                                                                                                                                  |                                     | Date: 2023.05.17    |
|                                                                                                                                                                                                                                                                                                                                                                                  |                                     | 14:56:40 +05'30'    |
|                                                                                                                                                                                                                                                                                                                                                                                  | <b>Sanjay V Patel</b>               |                     |
| <b>Place : Sojitra</b>                                                                                                                                                                                                                                                                                                                                                           | <b>Chairman</b>                     |                     |
| <b>Date : 17/05/2023</b>                                                                                                                                                                                                                                                                                                                                                         | <b>DIN No. : 00370715</b>           |                     |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

| STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31st MARCH, 2023 |                                        |                                        |
|-----------------------------------------------------------------------|----------------------------------------|----------------------------------------|
|                                                                       |                                        | (Rs. In Lacs)                          |
| Particular                                                            | For the Year ended<br>31st March, 2023 | For the Year ended<br>31st March, 2022 |
| <b>A. Cash Flow from Operating Activities</b>                         |                                        |                                        |
| <b>Net Profit / (Loss) before Tax</b>                                 | <b>1295.30</b>                         | <b>863.23</b>                          |
| <b>Adjustments for :</b>                                              |                                        |                                        |
| Depreciation and Amortization                                         | 133.88                                 | 63.12                                  |
| Financial Cost                                                        | 310.48                                 | 170.25                                 |
| Interest Received                                                     | 1.96                                   | 3.04                                   |
| Other Adjustment non cash items -currency fluctuation<br>reerseve     | -3.08                                  | -2.74                                  |
| Non Controlling Interest                                              | -32.74                                 | -57.93                                 |
| <b>Other Non Operating income</b>                                     |                                        |                                        |
| Operating Profit before working capital changes                       | 1705.80                                | 1038.97                                |
| <b>Adjustments for (increase)/Decrease in operating assets :</b>      |                                        |                                        |
| Trade Receivable                                                      | -4.04                                  | -390.54                                |
| Invetories                                                            | -335.60                                | -697.72                                |
| Loans and Advances                                                    | -186.86                                | -294.23                                |
| Other Current Assets                                                  | -183.55                                | -92.38                                 |
| <b>Adjustments for increase/(Decrease) in operating liabilities :</b> |                                        |                                        |
| Trade Payable                                                         | -498.91                                | -6.18                                  |
| Other Non Current Laibilities                                         | -356.27                                | 783.07                                 |
| Other Financial Liabilities- Current                                  | 1028.19                                | 417.78                                 |
| Other Current Liabilities                                             | -29.16                                 | 438.12                                 |
| Provisions                                                            | 31.37                                  | 178.37                                 |
| Increase / (Decrease) in Non Current Assets                           |                                        |                                        |
| <b>Cash Generated From Operations</b>                                 | <b>1170.96</b>                         | <b>1375.27</b>                         |
| Direct Tax                                                            | 311.99                                 | 195.69                                 |
| Indirect Tax                                                          |                                        |                                        |
| <b>Net Cash From Operating Activities (A)</b>                         | <b>858.96</b>                          | <b>1179.57</b>                         |



FDA & ISO 9001 : 2015 Certified Manufacturing Co.

**Corporate Office Address :**  
 Suite # 205, Sigma Prime, 2nd Floor, Nr. Sardar Patel Statue  
 Vallabh Vidhyanagar, Dist. Anand-388120, Gujarat, India  
 info@infiniumpharmachem.com, infinium\_11@yahoo.com  
 +91-2692-238849, 238850, 297446  
 www.infiniumpharmachem.com  
**R.O. & Factory Address :**  
 Plot No. 37-38-39, GIDC Sojitra, Dist. Anand-387240,  
 Gujarat, India Tel/fax : +91-2697-234987, 234004  
 CIN No U24231GJ2003PLC043218

|                                                               |                                                                                                     |                |
|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|----------------|
| <b>B. Cash Flow from Investing Activities</b>                 |                                                                                                     |                |
| Purchase of Tangible Fixed Assets (Gross)                     | -746.62                                                                                             | -472.69        |
| Purchase of Intangible Fixed Assets (Gross)                   | 0.00                                                                                                | 0.00           |
| Increase / (Decrease) in Non Current Assets                   | 0.00                                                                                                | 0.00           |
| Non controlling Interest (BS)                                 | 40.14                                                                                               | 62.62          |
| Long term Loans and Advances                                  | -19.68                                                                                              | -4.57          |
| Other Non Current Assets                                      | 232.48                                                                                              | -245.48        |
| Interest Received                                             | -1.96                                                                                               | -3.04          |
| Other Non Operating income                                    | 0.00                                                                                                | 0.00           |
| <b>Net Cash used in Investing Activities (B)</b>              | <b>-495.64</b>                                                                                      | <b>-663.15</b> |
| <b>C. Cash Flow from Financing Activities</b>                 |                                                                                                     |                |
| Proceeds from Issuing share                                   | 0.00                                                                                                | 0.00           |
| Interest /Finacial Charges Paid                               | -310.48                                                                                             | -170.25        |
| <b>Net Cash used in Financing Activities (C)</b>              | <b>-310.48</b>                                                                                      | <b>-170.25</b> |
|                                                               |                                                                                                     |                |
| <b>Net Increase / (Decrease) in cash and cash equivalents</b> | <b>52.85</b>                                                                                        | <b>346.17</b>  |
| <b>Cash and cash equivalents at the beginning of the year</b> | <b>545.16</b>                                                                                       | <b>198.99</b>  |
| <b>Cash and cash equivalents at the end of the year</b>       | <b>598.01</b>                                                                                       | <b>545.16</b>  |
|                                                               | <b>For, INFINIUM PHARMACHEM LTD</b>                                                                 |                |
|                                                               | Digitally signed by<br>SANJAYKUMAR<br>VITHTHALBHAI<br>PATEL<br>Date: 2023.05.17<br>14:56:56 +05'30' |                |
|                                                               | <b>Sanjay V Patel</b>                                                                               |                |
| <b>Place : Sojitra</b>                                        | <b>Chairman</b>                                                                                     |                |
| <b>Date : 17/05/2023</b>                                      | <b>DIN No. : 00370715</b>                                                                           |                |

## **DECLARATION**

**Under regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016,**

It is hereby declared and confirmed that the Auditors' Report on Annual Audited Standalone financial results for the year ended on March 31, 2023 and Annual Audited Consolidated financial results for the year ended on March 31, 2023 of the company is with unmodified opinion.

We further declare that M/s Ashok Rajpara & Co., Chartered Accountants (FRN : 153195W), the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the audited Standalone and Consolidated financial results of the Company for the period ended on March 31, 2023.

This declaration is issued in compliance of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2016.

Kindly take the same on your record.

### **For Infinium Pharmachem Limited**

SANJAYKUMAR Digitally signed by  
SANJAYKUMAR  
VITHTHALBHAI VITHTHALBHAI PATEL  
PATEL Date: 2023.05.17 14:57:14  
+05'30'

**Sanjaykumar Viththalbhai Patel**  
**Managing Director**  
**DIN: 00370715**

**Date:** May 17, 2023

**Place:** Sojitra, Anand

# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

INDEPENDENT AUDITORS' REPORT on Audited Standalone yearly financial Results of INFINIUM PHARMACHEM LIMITED Pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board Of Directors of  
INFINIUM PHARMACHEM LIMITED  
Plot No. 37-38, Sojitra GIDC,  
Dist : Anand, Gujarat

### **Opinion**

We have audited the accompanying standalone annual financial results of INFINIUM PHARMACHEM LIMITED ("the company"), for the year ended 31st March, 2023 attached herewith, being submitted by the company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the statement :

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the accounting principles generally accepted in India of the state of affairs of the company as at 31<sup>st</sup> March 2023, its profit / loss, changes in equity and its cash flows for the year ended on that date.

### **Basis for Opinion**

We conducted our audit of the standalone financial statements in accordance with the standards on Auditing specified under Section 143(10) of the Act. Our responsibility under those standards are further described in Auditor's Responsibility for the Audit of the standalone financial statements section of our report. We are independent of the company in accordance of with code of ethics issued by ICAI together with the independent requirements that are relevant to our audit of standalone financial statement under the provisions of the Act and the rule made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the stand-alone financial statement.

Previous year's half yearly financial results for the period ended on 31<sup>st</sup> March, 2022 is not prepared. The Company is listed on 17<sup>th</sup> April, 2023 and hence to maintain half yearly data was not the applicable during the year 2021-22.



A/510, Diamond World, Nr. Mini Bazar, Varachha Road, Surat. Gujarat- 395006  
Ph. 9824745000 Email: carajpara@gmail.com

# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

---

### **Management`s and Those Charged with Governance Responsibilities for the Statement**

This statement has been prepared on the basis of the standalone annual financial statements. The company`s Board of Directors is responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit/loss and other financial information of the company in accordance with the accounting principles generally accepted in India, including AS prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors is responsible for assessing the Company`s ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company`s financial reporting process.

### **Auditor`s Responsibility**

Our objectives are to obtain reasonable assurance about whether standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor`s report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these standalone financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit, We also;

- Identify and assess the risk of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedure responsive to those risk, and obtain evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omission, misrepresentation, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has

# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

adequate internal financial control system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

we also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matter**

The statement includes the financial results for the half year ended 31<sup>st</sup> March 2023, being the balancing figures between the audited figures in respect of the full financial year and the audited year-to-date figures up to the first half of the current financial year, which were subject to audit by us.

FOR, ASHOK RAJPARA & CO  
Chartered Accountants



Place: SURAT  
Date : 17/05/2023

  
(Ashok M. Rajpara)

Proprietor  
Membership No. 100559  
FRN : 153195W

UDIN : 23100559BGWQHB4439

# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

INDEPENDENT AUDITORS` REPORT on Audited Consolidated yearly financial Results of  
pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements)  
Regulations, 2015 (as amended)

To the Board Of Directors of  
INFINIUM PHARMACHEM LIMITED  
Plot No. 37-38, Sojitra GIDC,  
Dist : Anand, Gujarat

### **Opinion**

We have audited the accompanying consolidated annual financial results of INFINIUM PHARMACHEM LIMITED ("the Holding Company) and its subsidiaries (the Holding Company and its subsidiary together referred to as " Group") FOR THE YEAR ENDED 31<sup>ST</sup> March 2023, attached herewith, pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the statement :

- i. Includes the result f following subsidiary :
  - a) Infinium Green Energy Private Limited
  - b) Shanghai Tajilin Industrial Co. Limited
- ii. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- iii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the accounting principles generally accepted in India of the state of affairs of the company as at 31<sup>st</sup> March 2023, its profit / loss, changes in equity and its cash flows for the year ended on that date.

### **Basis for Opinion**

We conducted our audit of the consolidated financial statements in accordance with the standards on Auditing specified under Section 143(10) of the Act. Our responsibility under those standards are further described in Auditor`s Responsibility for the Audit of the consolidated financial statements section of our report. We are independent of the company in accordance of with code of ethics issued by ICAI together with the independent requirements that are relevant to our audit of consolidated financial statement under the provisions of the Act and the rule made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI`s code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the stand-alone financial statement.

Previous year`s half yearly financial results for the period ended on 31<sup>st</sup> March, 2022 is not prepared. The Company is listed on 17<sup>th</sup> April, 2023 and hence to maintain half yearly data was not the applicable during the year 2021-22.

# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

---

### **Management`s and Those Charged with Governance Responsibilities for the Statement**

These consolidated statement has been prepared on the basis of the standalone annual financial statements. The company`s Board of Directors is responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit/loss and other financial information of the company in accordance with the accounting principles generally accepted in India, including AS prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that gives s true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the consolidated statement, the Board of Directors is responsible for assessing the Company`s ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company`s financial reporting process.

### **Auditor`s Responsibility**

Our objectives are to obtain reasonable assurance about whether consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor`s report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these consolidated financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit, We also;

- Identify and assess the risk of material misstatement of the consolidated financial statements, weather due to fraud or error, design and perform audit procedure responsive to those risk, and obtain evidence that us sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud for one resulting from error, as fraud may involve collusion, forgery, intentional, omission, misrepresentation, or the override of internal control.

# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

---

- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial control system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

we also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matter**

The consolidated financial statement includes the unaudited financial results/financial information of one foreign subsidiary, whose financial result/financial information reflects total assets of Rs. 95472.00 thousands as at March 31, 2023, total revenue of Rs. 310536.88 thousands, net profit after tax of Rs. 8795.46 thousands for the year ended on that date, as considered in the consolidated financial statements, which have not been audited by its auditor. The subsidiary financial statements have been consolidated based on its management certified accounts.



# **ASHOK RAJPARA & CO**

## **Chartered Accountants**

---

The consolidated financial result includes the financial results for the half year ended 31<sup>st</sup> March 2023, being the balancing figures between the audited figures in respect of the full financial year and the audited year-to-date figures up to the first half of the current financial year, which were subject to audit by us.

FOR, ASHOK RAJPARA & CO  
Chartered Accountants



Place: SURAT  
Date : 17/05/2023

A handwritten signature in blue ink, appearing to read "Ashok M. Rajpara".

(Ashok M. Rajpara)  
Proprietor

Membership No. 100559  
FRN : 153195W

UDIN : **3100559BGWQHB4439**